(Head of Commercial: Mike Petroutsas, "Astellas") today announced final overall survival (OS) results from the Phase 3 EMBARK study evaluating XTANDI ® (enzalutamide), in combination with leuprolide ...

Details of the pilots and evaluations funded by HM Treasury's Labour Markets Evaluation and Pilots (LMEP) Fund. About the fundThe Labour Market ...

From Hokas to New Balance, these are the best walking shoes for wide feet, according to experts. They share why choosing the ...

Lane Bryant began as a maternity-wear brand and soon introduced dedicated plus-size lines, coining and legitimizing the term.

Plus-size activist and influencer Jaelynn Chaney has reportedly been keeping a low profile on social media after a run-in with the law earlier this year. The 29-year-old, known for her outspoken body ...

IO102-IO103 plus Keytruda improved median PFS by 8.4 months over Keytruda alone in advanced melanoma patients. The combination therapy showed a significant PFS benefit in PD-L1–negative patients, with ...

Dianne didn't appear in last week's show and faced conspiracy theories PREGNANT Strictly star Dianne Buswell is selling off her size 8 clothing ahead of the birth of her first child. The Australian ...

Enfortumab vedotin and pembrolizumab with surgery significantly improve outcomes in cisplatin-ineligible MIBC patients, reducing disease progression or death risk by 60%. The EV-303/KEYNOTE-905 trial ...

TOKYO and NEW YORK, Oct. 18, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. (NYSE: PFE) today announced positive results from the ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from the pivotal Phase 3 KEYNOTE-B96 trial, also known as ENGOT-ov65, ...

Every time Sarah publishes a story, you’ll get an alert straight to your inbox! Enter your email By clicking “Sign up”, you agree to receive emails from ...

"TECVAYLI is the most utilized BCMA bispecific in later lines of myeloma treatment, supported by extensive clinical and real-world evidence. These results demonstrate the clinical benefits of TECVAYLI ...